825 related articles for article (PubMed ID: 26944023)
1. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL; Ratziu V; Harrison SA; Abdelmalek MF; Aithal GP; Caballeria J; Francque S; Farrell G; Kowdley KV; Craxi A; Simon K; Fischer L; Melchor-Khan L; Vest J; Wiens BL; Vig P; Seyedkazemi S; Goodman Z; Wong VW; Loomba R; Tacke F; Sanyal A; Lefebvre E
Hepatology; 2018 May; 67(5):1754-1767. PubMed ID: 28833331
[TBL] [Abstract][Full Text] [Related]
3. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
[TBL] [Abstract][Full Text] [Related]
5. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
Tacke F
Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
8. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
9. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.
Anstee QM; Neuschwander-Tetri BA; Wai-Sun Wong V; Abdelmalek MF; Rodriguez-Araujo G; Landgren H; Park GS; Bedossa P; Alkhouri N; Tacke F; Sanyal AJ
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):124-134.e1. PubMed ID: 37061109
[TBL] [Abstract][Full Text] [Related]
10. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
12. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
Francque SM; Hodge A; Boursier J; Younes ZH; Rodriguez-Araujo G; Park GS; Alkhouri N; Abdelmalek MF
Hepatol Commun; 2024 Feb; 8(2):. PubMed ID: 38285756
[TBL] [Abstract][Full Text] [Related]
13. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
[TBL] [Abstract][Full Text] [Related]
17. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
18. Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.
Sherman KE; Abdel-Hameed E; Rouster SD; Shata MTM; Blackard JT; Safaie P; Kroner B; Preiss L; Horn PS; Kottilil S
Clin Infect Dis; 2019 May; 68(11):1911-1918. PubMed ID: 30239650
[TBL] [Abstract][Full Text] [Related]
19. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
